Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Acquisitions (Details) - USD ($) $ / shares in Units, $ in Millions					11 Months Ended	12 Months Ended
		Nov. 17, 2021	Jul. 30, 2019	Jul. 01, 2019	Nov. 16, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired						$ 0	$ 0	$ 10,861
Finite-lived intangible asset, useful life						8 years
Goodwill	[1]					$ 49,208	49,556	48,181
Trillium [Member]
Business Acquisition [Line Items]
Ownership percentage					2.00%
Trillium [Member]
Business Acquisition [Line Items]
Asset acquisition, share price (in dollars per share)		$ 18.50
Asset acquisition, consideration transferred		$ 2,000
Charge to research and development expenses in connection with asset acquisition		2,100				$ 2,100
Asset acquisition, assets acquired		256
Asset acquisition, liabilities assumed		$ 81
Therachon Asset Acquisition [Member]
Business Acquisition [Line Items]
Asset acquisition, consideration transferred				$ 322
Charge to research and development expenses in connection with asset acquisition				337
Upfront payment				340
Maximum potential milestone payments				470
Payments to acquire asset				317
Asset acquisition, consideration transferred, equity interest				$ 5
Array [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)			$ 48
Payments to acquire businesses, cash portion			$ 11,200
Cash payments for acquisition, net of cash acquired			10,900
Intangible assets			6,300
Goodwill			6,100
Net deferred tax liabilities			1,100
Assumed long-term debt			451
Array [Member] | Restructuring Charges And Acquisition-Related Costs [Member]
Business Acquisition [Line Items]
Post closing compensation expense								$ 157
Developed Technology Rights [Member]
Business Acquisition [Line Items]
Finite-lived intangible asset, useful life						7 years
Developed Technology Rights [Member] | Array [Member]
Business Acquisition [Line Items]
Identifiable intangible assets			$ 2,000
Acquired intangible assets, useful life			16 years
IPR&D [Member] | Array [Member]
Business Acquisition [Line Items]
Identifiable intangible assets			$ 2,800
Reduction in intangible assets due to measurement period adjustments							$ 900
Licensing Agreements [Member] | Array [Member]
Business Acquisition [Line Items]
Intangible assets			1,500
Licensing Agreements, Technology In Development [Member] | Array [Member]
Business Acquisition [Line Items]
Intangible assets			1,200
Licensing Agreements, Developed Technology [Member] | Array [Member]
Business Acquisition [Line Items]
Identifiable intangible assets			$ 360
Finite-lived intangible asset, useful life			10 years

[1] As a result of the reorganization of our commercial operations during the fourth quarter of 2021 (see Note 17), we were required to estimate the relative fair values of our PC1 and Hospital organizations to determine any reallocation of goodwill. We completed this analysis and determined that no goodwill was required to be reallocated. As a result, our entire goodwill balance continues to be assigned within the Biopharma reportable segment.